BofA keeps Elan as top pick in animal health sector ahead of 2Q26 By Investing.com
Bank of America said animal health stocks face continued 2Q26 pressure from fewer veterinary visits and higher drug competition. It kept Elanco Animal Health (Elanco) as its top pick with a buy rating, while maintaining neutral ratings on Zoetis and Idexx Laboratories. VetSource data showed Q2 visits down 1.9% YoY and July down 4% YoY. BofA expects FY2026 visits to fall about 2% and sees Elanco pricing rising below Zoetis.
How this was made
The 30-second read
Why it matters
The main tradable takeaway is relative positioning: Elanco is the top pick with a more favorable catalyst profile, while Zoetis and Idexx remain neutral amid continued visit declines and competitive pressure.
Market read
For traders, this is a pre-earnings positioning update that may influence relative performance into 2Q26, but it lacks new company-specific fundamentals.
What to watch
The article emphasizes visit declines and competition but does not quantify how much pricing, mix, or new product cycles offset volume weakness for each company.
Background
BofA discusses animal health sector pressure into 2Q26 earnings, using VetSource veterinary visit trends and a third-party forecast.
Ticker impact
BofA keeps Elanco as its top pick, citing a clearer catalyst profile and potential estimate increases despite sector headwinds.
Modest upside bias versus neutral-rated peers, but likely limited without new company-specific datapoints.
The article is an analyst reiteration, not a new Elanco print. The incremental trading signal is relative positioning (top pick) plus channel-check pricing commentary.
BofA maintains a neutral rating on Zoetis, pointing to near-term headwinds from competition and negative sentiment.
Downside or underperformance risk versus Elanco if the market focuses on continued visit declines and competition.
The newest facts are the VetSource visit decline context and BofA’s view that competition remains a key drag. No new Zoetis-specific operational update is provided.
BofA keeps Idexx neutral, expecting 2Q results to align with estimates, while noting pressure tied to forecasted continued visit declines.
Limited catalyst upside; shares may trade with sector sentiment unless results surprise.
The article provides sector datapoints (VetSource declines, CATalyst Council forecast) and BofA’s rating stance, but no new Idexx-specific guidance or results.
Market effects
Reinforces that veterinary-visit declines and increased drug competition are the dominant near-term drivers for animal health earnings.
No explicit regional impact beyond US-focused veterinary visit data.
Limited; the catalysts discussed are sector-wide and not tied to a specific geography.
Counterpoint
If veterinary visits stabilize sooner than BofA expects, the ‘continued decline’ narrative could reverse quickly, benefiting the neutral-rated names.
Key entities
- companyElanco Animal Health
BofA’s top pick in animal health, supported by a clearer catalyst profile and pricing power.
- companyZoetis
Neutral-rated by BofA, with competition and negative sentiment highlighted despite valuation lows.
- companyIDEXX Laboratories
Neutral-rated by BofA, with expectations for 2Q results to align and risk tied to continued visit declines.
- data_providerVetSource
Used for veterinary visit data showing YoY declines in 2Q and July.
- research_firmCATalyst Council
Forecasts continued visit declines past 2030, including a 2027 trough.
